Clinical Trials & Research

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 11, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed case accrual for the first interim analysis of the Phase 3 COVE study of mRNA-1273, its COVID-19 vaccine candidate. Moderna has seen
0 Comments
Nov 13 2020 Porvair Sciences reports, due to promising results, it has agreed with its collaborative partners to make additional investment in the CEAT project** which aims to dramatically improve the diagnosis and treatment of ovarian cancer. In the initial stage of the CEAT (Cluster for Epigenomic and Antibody Drug Conjugate Therapeutics) project – Porvair
0 Comments
12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. The addition of Calquence to best supportive care (BSC) did not increase the proportion of patients who remained alive and free of respiratory failure. No new safety signal for Calquence was observed in the
0 Comments
Nov 12 2020 A new center at the University of Cambridge, in collaboration with AstraZeneca and GSK, aims to use AI to make medical discoveries, accelerate the development of precision medicine and develop new treatments On 11 November the University of Cambridge announced a five-year agreement with AstraZeneca and GSK to fund the Cambridge Centre
0 Comments
Daix (France), November 10, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced conclusions from its end-of-phase II meeting with the U.S. Food and Drug
0 Comments
Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, infects host cells via the spike proteins on the virus surface.
0 Comments
PRINCETON, N.J.–(BUSINESS WIRE) November 3, 2020 — Bristol Myers Squibb (NYSE:BMY) today announced positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis. POETYK PSO-1 evaluated 6 mg of deucravacitinib once
0 Comments
Reviewed by Emily Henderson, B.Sc.Nov 6 2020 A new study has shown pregnant women with obesity could reduce the health risks for their infants through improved diet and more physical activity. Research published today in the journal PLosMed investigates the impact of high glucose in mothers with gestational diabetes mellitus (GDM) and changes to infants
0 Comments
OSLO, Norway and CHENGDU, China. 03 November,2020— CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will fund the development of the protein-based  S-Trimer COVID-19 vaccine candidate by Sichuan Clover Biopharmaceuticals, Inc (China) (“Clover”) through a global pivotal Phase 2/3 efficacy clinical trial and to licensure in China and globally, if the vaccine is
0 Comments
Nov 6 2020 Eurofins, the global leader in the field of analytical services and a pioneer in food authenticity testing since its creation, is pleased to announce the launch of the TOFoo (True Organic Food) project. The aim of this collaborative project, comprised of five partners from the food industry, laboratory analysis, and digital sectors,
0 Comments
GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) – Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Company’s COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community. “This arrangement with the
0 Comments
Nov 4 2020 REGENHU, a leading global bioprinting company, today announced the launch of the R-GEN platform and SHAPER, a new bioprinter and software designed to cover the entire biofabrication process. Bioprinting has experienced unpreceded growth in the past decade. This technique has evolved rapidly from developing printing biomaterials to tissues and more complex structures
0 Comments
NEW YORK–(BUSINESS WIRE) October 27, 2020 — Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate
0 Comments
INDIANAPOLIS, Oct. 28, 2020 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The U.S. government will accept the vials of bamlanivimab if it is granted an Emergency Use Authorization (EUA) by the U.S. Food
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 30 2020 The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive. A team of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to disrupt that dynamic so that cancer treatments can be more effective. Their
0 Comments
SARASOTA, Fla. and NOVATO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced positive interim data from the Phase 1/2 study of GTX-102. Preliminary results from the first five patients treated
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 26, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoing efforts to secure early
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 27 2020 Valleywise Health of Phoenix, America’s Essential Hospitals, and a dozen essential hospitals – those with a safety-net mission – joined together in an urgent call for all Americans to remain vigilant and continue preventive actions to combat the spread of COVID-19. As the nation faces a new surge
0 Comments
KENILWORTH, N.J.–(BUSINESS WIRE) October 20, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study, healthy adults 50 years of age or
0 Comments
21 October 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. In the midst of the global pandemic, the analysis found
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 21 2020 Artificial light abnormally increases mosquito biting behavior at night in a species that typically prefers to bite people during the day, according to research from the University of Notre Dame that was published in The American Journal of Tropical Medicine and Hygiene. Increased biting by Aedes aegypti mosquitoes,
0 Comments
October 16, 2020 — The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation — called
0 Comments